top of page
Empowering immune cells
to combat aggressive cancers
IIMPORTANT NOTICE: Adecto Pharmaceuticals ceased operations on September 30, 2026. The intellectual property for our breakthrough, ADAM8-targeting humanized monoclonal antibody technology is being transferred back to the inventors. The inventors welcome discussions regarding asset acquisition, licensing, or collaborative development. To explore these opportunities, please contact them directly at adecto.tech@gmail.com.
Adecto Pharmaceuticals is a pre-clinical stage company developing a treatment for cancers that do not respond to conventional immunotherapy.
Adecto's approach is to reprogram a larger set of the patient’s immune cells than conventional immunotherapy can achieve, resulting in a more powerful immune response against a variety of aggressive solid tumors, including colorectal, breast and kidney cancers.
Adecto is built on its founders' 30+ years of research hunting down molecules that can be safely targeted to stop both primary cancer growth and metastases.
bottom of page